Brooks Andrews joined EW in 2013 and became Managing Director in 2021.
Mr. Andrews led EW’s growth equity investments in Enercon Technologies and Sonendo, and he has played a key role as a Director or a Board Observer of EW growth equity portfolio companies GermFree Laboratories, Xenex, Axogen, Corium (acquired by Gurnet Point), EyePoint Pharmaceuticals (NASDAQ: EYPT), and ProteinSimple (acquired by BioTechne).
Prior to joining EW, Mr. Andrews worked at FFL Partners (“FFL”), a growth-oriented private equity firm focused on business and healthcare services based in San Francisco. At FFL, he worked on several healthcare services investments including IT, dental, practice management, and urgent care. Prior to FFL, Mr. Andrews worked at Barclay’s Capital in the firm’s investment banking division, focusing on financings, mergers, and acquisitions in the communications and media industries.
Mr. Andrews received Bachelor of Business Administration degrees in Economics and Finance and a Master of Arts degree in Economics from the University of Georgia, and a Master of Business Administration degree from Stanford University.